{"id":650370,"date":"2023-05-04T17:54:01","date_gmt":"2023-05-04T17:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=650370"},"modified":"2023-05-04T17:54:01","modified_gmt":"2023-05-04T17:54:01","slug":"sarcoidosis-market-research-report-epidemiology-and-competitive-insights-2032-companies-relief-therapeutics-holdings-atyr-pharma-amgen-bristolmyers-squibb-novartis-pfizer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sarcoidosis-market-research-report-epidemiology-and-competitive-insights-2032-companies-relief-therapeutics-holdings-atyr-pharma-amgen-bristolmyers-squibb-novartis-pfizer_650370.html","title":{"rendered":"Sarcoidosis Market Research Report, Epidemiology, and Competitive Insights 2032 | Companies – Relief Therapeutics Holdings, aTyr Pharma, Amgen, Bristol-Myers Squibb, Novartis, Pfizer"},"content":{"rendered":"
\n
\"Sarcoidosis<\/a><\/div>\n
\n
Sarcoidosis Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Sarcoidosis – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Sarcoidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInisght launched a new report on Sarcoidosis Market Insights, Epidemiology and Market Forecast 2032.<\/strong><\/p>\n

DelveInsight’s “Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>” report delivers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Sarcoidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Sarcoidosis is a multisystem disorder of unknown etiology characterized by the presence of noncaseating granulomas in organs. This condition mostly affects young adults and characteristically presents with reticular opacities in the lungs and bilateral hilar lymphadenopathy. Other involved sites include eyes, skin, and joints, and in some cases, the reticuloendothelial system, musculoskeletal system, exocrine glands, heart, kidney, and central nervous system. This activity outlines the evaluation and management of sarcoidosis and explains the role of the interprofessional team in improving care for patients with this condition. It is an inflammatory disease of unknown etiology that manifests as noncaseating granulomas in multiple systems. Various associations have been described, including occupational and environmental exposures to beryllium, dust, and other agents causing asthma. Various microorganisms like mycobacteria and propionibacteria have been associated. Possible infective etiology has been described in a few studies where sarcoidosis developed in a previously negative individual after cardiac or bone marrow transplantation.<\/p>\n

“The prevalence of Sarcoidosis is generally higher among the female population as compared to males.”<\/strong><\/p>\n

Sarcoidosis Key Companies<\/a>:<\/strong><\/p>\n

• Relief Therapeutics Holdings<\/p>\n

• aTyr Pharma<\/p>\n

• Amgen<\/p>\n

• Bristol-Myers Squibb<\/p>\n

• Novartis<\/p>\n

• Pfizer<\/p>\n

• United Therapeutics Corporation<\/p>\n

Sarcoidosis Emerging Drugs<\/strong><\/p>\n

RLF-100: Relief Therapeutics<\/p>\n

RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients.<\/p>\n

Efzofitimod: aTyr Pharma<\/p>\n

Efzofitimod is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. Efzofitimod works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. aTyr is initially investigating efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause progressive fibrosis of the lung.<\/p>\n

Sarcoidosis Market Outlook<\/a><\/strong><\/p>\n

The Sarcoidosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Sarcoidosis market trends by analyzing the impact of current Sarcoidosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n

This segment gives a thorough detail of Sarcoidosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sarcoidosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n

According to DelveInsight, the Sarcoidosis market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/sarcoidosis-market<\/a><\/strong><\/p>\n

Table of contents<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

1 Key Insight<\/p>\n<\/td>\n<\/tr>\n

\n

2 Executive Summary of Sarcoidosis<\/p>\n<\/td>\n<\/tr>\n

\n

3 Sarcoidosis Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n

\n

4 Disease Background and Overview: Sarcoidosis<\/p>\n<\/td>\n<\/tr>\n

\n

5 Case Reports<\/p>\n<\/td>\n<\/tr>\n

\n

6 Sarcoidosis Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n

\n

7 United States Epidemiology<\/p>\n<\/td>\n<\/tr>\n

\n

8 EU5 Epidemiology<\/p>\n<\/td>\n<\/tr>\n

\n

9 Japan Epidemiology<\/p>\n<\/td>\n<\/tr>\n

\n

10 Current Sarcoidosis Treatment and Medical Practices<\/p>\n<\/td>\n<\/tr>\n

\n

11 Unmet needs<\/p>\n<\/td>\n<\/tr>\n

\n

12 Sarcoidosis Marketed Drugs<\/p>\n<\/td>\n<\/tr>\n

\n

13 Sarcoidosis Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n

\n

14 Sarcoidosis 7MM Market Analysis<\/p>\n<\/td>\n<\/tr>\n

\n

15 United States<\/p>\n<\/td>\n<\/tr>\n

\n

16 EU-5 countries: Market Outlook<\/p>\n<\/td>\n<\/tr>\n

\n

17 Japan Market Outlook<\/p>\n<\/td>\n<\/tr>\n

\n

18 Sarcoidosis Market Drivers<\/p>\n<\/td>\n<\/tr>\n

\n

19 Sarcoidosis Market Barriers<\/p>\n<\/td>\n<\/tr>\n

\n

20 SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n

\n

21 Reimbursement and market access<\/p>\n<\/td>\n<\/tr>\n

\n

22 Appendix<\/p>\n<\/td>\n<\/tr>\n

\n

23 DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n

\n

24 Disclaimer<\/p>\n<\/td>\n<\/tr>\n

\n

25 About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Download report: https:\/\/www.delveinsight.com\/report-store\/sarcoidosis-market<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Sarcoidosis Market DelveInsight’s “Sarcoidosis – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Sarcoidosis, historical and forecasted epidemiology as well as the Sarcoidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-650370","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=650370"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650370\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=650370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=650370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=650370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}